The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation
Fabre, M.A., Jones, D.C., Bunce, M., Morris, P.J., Friend, P.J., Welsh, K.I. and Marshall, S.E. (2004) The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation. Transplant International, 17 (9). pp. 531-539.
*Subscription may be required
Azathioprine metabolism is influenced by activity of the enzyme thiopurine S-methyltransferase (TPMT), which varies markedly between individuals. In this study we examined the influence of TPMT gene polymorphisms on azathioprine dose 1 year after renal transplantation. TPMT coding and promoter genotypes were determined using PCR-based assays. Azathioprine dose, white cell count, and intercurrent events throughout the first year after renal transplantation were ascertained from contemporaneous clinical notes. All patients analysed (n = 172) received an initial azathioprine dose of 1.5 mg/kg per day. Twelve individuals with one variant TPMT coding allele were detected (*3A n = 11, *3C n = 1). Of these, 58% required azathioprine dose reduction because of leucopenia, compared to only 30% of homozygous wild-type patients (P = 0.04). A significant correlation between the presence of ≥11 variable number tandem repeats (VNTRs) in the TPMT promoter and reduction in azathioprine dose was also identified (P = 0.001). We concluded that when azathioprine is administered at an initial dose of 1.5 mg/kg per day, both coding and promoter TPMT polymorphisms influence the dose tolerated.
|Publication Type:||Journal Article|
|Copyright:||© 2004 Springer-Verlag|
|Item Control Page|